Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-pdxrj Total loading time: 0 Render date: 2025-03-09T02:36:51.715Z Has data issue: false hasContentIssue false

Zonisamide

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Zonisamide (1-(1,2-Benzoxazol-3-yl)methanesulphonamide) is a sulphonamide derivative with a molecular weight of 212.2 and a molecular formula of C8H8N2O3S.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 527 - 536
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Goel, A, Sugumaran, R, Narayan, SK. Zonisamide in Parkinson’s disease: a current update. Neurol Sci 2021; 42(10): 4123–4129.CrossRefGoogle ScholarPubMed
Murata, M, Hasegawa, K, Kanazawa, I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007; 68(1): 45–50.CrossRefGoogle ScholarPubMed
Murata, M, Hasegawa, K, Kanazawa, I, Fukasaka, J, Kochi, K, Shimazu, R. Zonisamide improves wearing-off in Parkinson’s disease: a randomized, double-blind study. Mov Disord 2015; 30(10): 1343–1350.CrossRefGoogle ScholarPubMed
Murata, M, Odawara, T, Hasegawa, K, Iiyama, S, Nakamura, M, Tagawa, M, Kosaka, K. Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology 2018; 90(8): e664–e672.CrossRefGoogle ScholarPubMed

References

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 2 January 2023 via www.medicinescomplete.com.Google Scholar
Arawaka, S, Fukushima, S, Sato, H, Sasaki, A, Koga, K, Koyama, S, Kato, T. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson’s disease. PLoS One 2014; 9(2): e89076.CrossRefGoogle Scholar
Bermejo, PE, Ruiz-Huete, C, Anciones, B. Zonisamide in managing impulse control disorders in Parkinson’s disease. J Neurol 2010; 257(10): 1682–1685.CrossRefGoogle ScholarPubMed
Gluck, MR, Santana, LA, Granson, H, Yahr, MD. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity. J Neural Transm (Vienna) 2004; 111(6): 713–724.CrossRefGoogle ScholarPubMed
Kong, L, Xi, J, Jiang, Z, Yu, X, Liu, H, Wang, Z. Zonisamide’s efficacy and safety on Parkinson’s disease and dementia with Lewy bodies: a meta-analysis and systematic review. Biomed Res Int 2022; 2022: 4817488.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 2 January 2023 via www.medicinescomplete.com.Google Scholar
Matsunaga, S, Kishi, T, Iwata, N. Combination therapy with zonisamide and antiparkinson drugs for Parkinson’s disease: a meta-analysis. J Alzheimers Dis 2017; 56(4): 1229–1239.CrossRefGoogle ScholarPubMed
Summary of product characteristics – zonegran 50 mg hard capsules. Advanz Pharma. Electronic Medicines Compendium: Zonegran 50 mg hard capsules – summary of product characteristics (SmPC) – (emc). Accessed on 2 January 2023 via www.medicines.org.uk.Google Scholar
Yang, LP, Perry, CM. Zonisamide: in Parkinson’s disease. CNS Drugs 2009; 23(8): 703–711.CrossRefGoogle ScholarPubMed
Zonisamide. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 2 January 2023 via www.medicinescomplete.com.Google Scholar
Zonisamide. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 2 January 2023 via www.micromedexsolutions.com.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Zonisamide
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.053
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Zonisamide
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.053
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Zonisamide
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.053
Available formats
×